- Report
- March 2025
- 250 Pages
Global
From €4285EUR$4,490USD£3,590GBP
- Report
- February 2025
- 200 Pages
Global
From €4285EUR$4,490USD£3,590GBP
- Report
- August 2024
- 175 Pages
Global
From €4772EUR$5,000USD£3,998GBP
- Report
- May 2024
- 132 Pages
Global
From €6203EUR$6,499USD£5,197GBP
- Report
- February 2025
- 185 Pages
Global
From €4295EUR$4,500USD£3,598GBP
- Report
- April 2024
- 185 Pages
Global
From €4295EUR$4,500USD£3,598GBP
- Report
- January 2025
- 880 Pages
Global
From €7587EUR$7,950USD£6,357GBP
- Report
- June 2024
- 200 Pages
Global
From €7587EUR$7,950USD£6,357GBP
- Report
- June 2024
- 200 Pages
Global
From €7587EUR$7,950USD£6,357GBP
- Report
- June 2024
- 200 Pages
Global
From €7587EUR$7,950USD£6,357GBP
- Report
- June 2024
- 200 Pages
Global
From €7587EUR$7,950USD£6,357GBP
- Report
- June 2024
- 200 Pages
Global
From €7587EUR$7,950USD£6,357GBP
- Report
- June 2024
- 200 Pages
Global
From €7587EUR$7,950USD£6,357GBP
- Report
- August 2024
- 200 Pages
Global
From €3692EUR$3,869USD£3,094GBP
- Clinical Trials
- November 2024
- 450 Pages
Global
From €4772EUR$5,000USD£3,998GBP
- Report
- June 2024
- 200 Pages
Global
From €7587EUR$7,950USD£6,357GBP
- Report
- June 2024
- 200 Pages
Global
From €7587EUR$7,950USD£6,357GBP
- Report
- August 2024
- 150 Pages
Global
From €4629EUR$4,850USD£3,878GBP
- Report
- August 2024
- 150 Pages
Global
From €4629EUR$4,850USD£3,878GBP
- Report
- October 2024
- 140 Pages
Global
From €3770EUR$3,950USD£3,159GBP

Lung cancer is a type of cancer that originates in the lungs. It is the leading cause of cancer-related death worldwide. Oncology is the branch of medicine that deals with the diagnosis, treatment, and prevention of cancer. Lung cancer is one of the most common types of cancer treated by oncologists. Treatment options for lung cancer include surgery, chemotherapy, radiation therapy, and targeted therapy.
The lung cancer market is a rapidly growing segment of the oncology market. It is driven by the increasing prevalence of lung cancer, advances in treatment options, and the increasing availability of targeted therapies. The market is expected to continue to grow in the coming years due to the increasing demand for better treatments and the development of new therapies.
Some companies in the lung cancer market include AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Merck, Novartis, Pfizer, and Roche. Show Less Read more